AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings

Pascal Soriot, AstraZeneca CEO (Photographer: Jose Sarmento Matos/Bloomberg via Getty Images) July 27, 2026 07:08 AM EDT AIPharma As­traZeneca looks to AI to ease risk in late-stage tri­als, speed up fil­ings Elizabeth Cairns Senior biopharma journalist As­traZeneca’s use of AI in drug de­sign and de­vel­op­ment has not yet yield­ed any clin­i­cal-stage can­di­dates, CEO Pas­cal So­ri­ot said Mon­day, but he added it … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER